Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer — Neutral
IOVA GlobeNewsWire — February 10, 2025SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.
MU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Micron Technology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
MU Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").
AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
AZN Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").
Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 — Neutral
ISPR PRNewsWire — February 10, 2025Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer — Neutral
NCNA Business Wire — February 10, 2025SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.
CRBU STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
CRBU Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").
Tilray Brands Enhances Global Cannabis Supply Chain — Neutral
TLRY GlobeNewsWire — February 10, 2025Tilray Brands Enhances Global Cannabis Supply Chain Increases Industry-Leading Capacity to Meet Global Demand, Driving Growth Across Canada and Europe
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones — Neutral
INCY Business Wire — February 10, 2025WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry — Neutral
EKSO GlobeNewsWire — February 10, 2025Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States
PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside.
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma — Neutral
BMY Business Wire — February 10, 2025PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.
Sempra Appoints Anya Weaving and Kevin Sagara to Board of Directors — Neutral
SRE PRNewsWire — February 10, 2025SAN DIEGO , Feb. 10, 2025 /PRNewswire/ -- Sempra (NYSE: SRE) today announced the appointments of Anya Weaving and Kevin Sagara to the company's board of directors effective March 1, 2025. Weaving's extensive investment banking experience, where she advised clients in the oil and gas industry on strategy, mergers and acquisitions (M&A) and capital markets transactions, combined with her previous role as a chief financial officer, brings industry knowledge and critical skills in strategic decision-making, financial acumen and governance to the board.
DALLAS--(BUSINESS WIRE)--AECOM, the trusted global infrastructure leader, today announced key leadership appointments to further strengthen its global operations and enhance client delivery. Bane Gaiser has been named Buildings + Places Global Business Line Chief Executive, Richard Whitehead as Europe & India Regional Chief Executive, and Sam Donelson as U.S. East & Latin America Regional Chief Executive. With extensive industry experience, including long-standing careers at AECOM, thes.
Helmerich & Payne Q1 Earnings Surpass Estimates, Revenues Lag — Positive
HP Zacks Investment Research — February 10, 2025HP's Q1 2025 results show that the North America Solutions segment outperforms, but the International Solutions segment lags.
Gold (XAU) Price Forecast: Safe-Haven Demand Surges as Trump's Tariff Plans Shake Markets — Positive
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL FXEmpire — February 10, 2025Gold surges past $2,900 as Trump's tariff threats fuel safe-haven demand. Will inflation data and Fed policy drive XAU/USD toward the $3,000 milestone?
Shares of Palantir Technologies (PLTR -0.39%) have been one of the best-performing artificial intelligence (AI) stocks over the past few years. Another blowout earnings report sent the stock surging in early February.
Brookfield to Invest €20 billion in France's AI Infrastructure — Neutral
BAM GlobeNewsWire — February 10, 2025Investment in data centers and associated infrastructure to be delivered by 2030 led by Paris-headquartered Data4 Investment in data centers and associated infrastructure to be delivered by 2030 led by Paris-headquartered Data4
Will Potential Tariffs on Taiwan Semiconductor Manufacturing Sink the Stock? — Negative
TSM The Motley Fool — February 10, 2025Taiwan is a global chip manufacturing hot spot, home to companies like Taiwan Semiconductor Manufacturing (TSM -2.08%), which fabricates chips used in nearly every high-end technology. TSMC is a vital supplier to the artificial intelligence (AI) computing power arms race, and slapping a tariff on products that come from Taiwan could be a big hurdle for domestic AI companies to clear.